ABNOM
☆ Yng nghanlyniadau Stiftung Warentest 2022 o’r Almaen, roedd boddhad defnyddwyr â ModelDerm ond ychydig yn is nag ymgynghoriadau telefeddygaeth taledig.
References
Mae'n hysbys bod y laser Q-switched Nd:YAG yn trin nevus Ota a chyflyrau tebyg yn effeithiol. Fe wnaethom gynnal astudiaeth i weld pa mor dda yr oedd laser high-fluence 1064 nm Q-switched Nd:YAG yn gweithio ar smotiau Mongolaidd mewn mannau anarferol, heb achosi i'r croen ysgafnhau. Gwnaethom astudio 61 o gleifion â'r smotiau hyn, gan archwilio cyfanswm o 70 o friwiau. Cafodd hanner y briwiau eu trin â'r laser, tra bod eraill heb eu trin er mwyn eu cymharu. Fe wnaethom werthuso'r canlyniadau gan ddefnyddio graddfa a dyfais o'r enw Mexameter® i fesur lefelau melanin. Dilynwyd cleifion am gyfartaledd o 14 mis yn y grŵp triniaeth a 18 mis yn y grŵp arsylwi. Ar ddiwedd yr astudiaeth, canfuom wahaniaethau sylweddol yn y sgorau graddfa a lefelau melanin rhwng y grwpiau a gafodd eu trin a'r grwpiau heb eu trin, gyda'r grŵp a gafodd ei drin â laser yn dangos canlyniadau gwell. Roedd y laser high-fluence Q-switched Nd:YAG , heb achosi mellt ar y croen, yn effeithiol ac yn ddiogel ar gyfer trin y smotiau Mongolaidd anarferol hyn.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Fe wnaethom astudio effeithiolrwydd a diogelwch defnyddio triniaeth laser benodol ar gyfer ABNOM , ac edrych ar ba ffactorau a allai effeithio ar ba mor dda y mae'n gweithio. Gwnaethom edrych ar 110 o gleifion a gafodd ABNOM ac a gafodd rhwng dwy a naw triniaeth laser. Gwelsom fod y driniaeth yn gweithio'n well po hiraf y'i gwnaed, ond nid cystal mewn cleifion hŷn. Roedd hefyd yn gweithio'n well mewn cleifion â chroen ysgafnach (math III) ac ardaloedd llai yr effeithiwyd arnynt (llai na 10 cm2) . Roedd cael melasma ynghyd â ABNOM yn gwneud y driniaeth yn llai effeithiol. Nid oedd yn ymddangos bod lliw na nifer yr ardaloedd yr effeithiwyd arnynt yn gwneud gwahaniaeth. Cafodd tua 10% o gleifion smotiau tywyllach ar ôl triniaeth. Rhoddodd triniaeth lluosog gynnar ganlyniadau da. Mae cleifion hŷn â chroen tywyllach a smotiau tywyllach yn fwy tebygol o gael smotiau tywyllach ar ôl triniaeth. Ar gyfer cleifion â ABNOM a melasma, mae'n well defnyddio laser ynni is i osgoi gwaethygu'r melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Triniaeth
Anaml y bydd asiantau gwynnu yn helpu. Yn wahanol i melasma, gellir gwella ABNOM gyda thriniaeth laser a'i adael i gael ei dynnu heb ddigwydd eto. Gellir perfformio triniaeth laser 10 i 20 gwaith i drin ABNOM.
#QS1064 laser